Trial Profile
CS-747S PhaseIII trial -Non-inferiority study of CS-747S versus clopidogrel bisulfate in patients with ischemic cerebrovascular accident
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Jan 2024
Price :
$35
*
At a glance
- Drugs Prasugrel (Primary) ; Clopidogrel
- Indications Myocardial infarction; Stroke
- Focus Adverse reactions; Therapeutic Use
- Acronyms PRASTRO-I
- Sponsors Daiichi Sankyo Company
- 24 Dec 2021 According to a Daiichi Sankyo Company media release, the company has obtained a supplemental new drug application approval for additional indication and dosage and administration of the antiplatelet agents "Efient 3.75 mg Tablets" and "Efient 2.5 mg Tablets" in Japan.
- 10 Feb 2021 Results (n=3747) of post hoc analysis assessing association between blood pressure levels and the risk of recurrent stroke, published in the Stroke
- 15 Dec 2020 According to a Daiichi Sankyo Company media release, the supplemental application is based on the results of a phase 3 study in thrombotic stroke patients in Japan (PRASTRO-III study), as well as other phase 3 studies in Japan targeting patients with ischemic cerebrovascular disease (PRASTRO-I and PRASTRO-II studies).